Estimates of pertussis vaccine effectiveness in United States air force pediatric dependents |
| |
| Affiliation: | 1. United States Air Force School of Aerospace Medicine, 2510 5th Street, Bldg 840, Wright-Patterson AFB, OH 45433, United States;2. Solutions Through Innovative Technologies, 3152 Presidential Drive, Fairborn, OH 45324, United States;1. Tianjin Centers for Disease Control and Prevention, Tianjin 300011, China;2. Hangu Centers for Disease Control and Prevention, Tianjin 300480, China;1. Ciber de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, España;2. Departamento de Salud Pública, Facultad de Medicina, Universidad de Barcelona, Barcelona, España;1. Univ. Lille, U1019, UMR 8204, CIIL – Centre for Infection and Immunity of Lille, F-59000 Lille, France;2. CNRS, UMR 8204, F-59000 Lille, France;3. Inserm, U1019, F-59000 Lille, France;4. CHU Lille, F-59000 Lille, France;5. Institut Pasteur de Lille, F-59000 Lille, France;1. Department of Public Health, Osaka City University Faculty of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan;2. Section of Pediatrics, Department of Medicine, Fukuoka Dental College, 2-15-1, Tamura, Sawara-ku, Fukuoka 814-0193, Japan;3. Department of Pediatrics, Kawasaki Medical School, 577, Matsushima, Kurashiki, Okayama 701-0192, Japan;4. Field Epidemiology Training Program, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan;5. Department of Preventive Medicine, Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga 849-8501, Japan;6. Sotobo Children''s Clinic, Medical Corporation Shigyo-no-kai, 1880-4, Izumi, Misaki-cho, Isumi 299-4503, Chiba, Japan;7. Clinical Epidemiology Research Center, Medical Co. LTA, 6-18, Ten-ya-machi, Hakata-ku, Fukuoka 812-0025, Japan;1. Jerusalem District Health Office, Ministry of health, Jerusalem, Israel;2. Braun School of Public Health and Community Medicine, The Hebrew University and Hadassah, Jerusalem, Israel |
| |
| Abstract: | BackgroundPertussis vaccination compliance is critical for reduction in the prevalence of disease; however, the current acellular pertussis vaccine may not provide sufficient protection from infection. This study examined acellular pertussis vaccine effectiveness (VE) for Air Force dependents less than 12 years of age.MethodsWe conducted a case-control study among Air Force pediatric dependents from 2011 to 2013, comparing cases with positive pertussis test results to controls who received the same lab tests with a negative result. Our study population was categorized by age group and vaccination status based on the Centers for Disease Control and Prevention recommended pertussis vaccination schedule. VE was calculated with respect to vaccination status and pertussis lab results.ResultsWe compared 27 pertussis laboratory positive cases with 974 pertussis laboratory negative controls, 2 months to <12 years old. Comparing completely vaccinated to non-vaccinated patients, the overall VE was 78.3% (95% confidence interval (CI): 48.6, 90.8; p < 0.001). VE was highest among those 15 months to <6 years old: 97.6% (95% CI: 78.5, 99.7; p < 0.001). Children 6 to <12 years old had the lowest VE: 48.5% (95% CI: ?74.0, 84.7; p = 0.28). Comparing partially vaccinated patients to nonvaccinated patients yielded 64.2% (95% CI: ?7.2, 88.1; p = 0.06) overall VE.ConclusionsAcellular pertussis vaccination was effective at preventing laboratory confirmed pertussis among our Air Force pediatric dependent population, with highest protection among completely vaccinated, young children. Older children received the lowest amount of protection. Partial vaccination had near significant protection. Our overall calculated pertussis VE corroborates other pertussis VE studies looking at similar age groups. |
| |
| Keywords: | Pertussis Vaccine effectiveness Immunization Department of defense |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
